Generic Seizure Drugs Vary Widely in Bioavailability (CME/CE)
Posted on 03. Jul, 2011 by Dr. Ellis in News and Updates
(MedPage Today) — Bioavailability of generic versions of epilepsy drugs was generally similar to that of their branded counterparts, but not so much when supposedly bioequivalent products were compared with each other, researchers said.
Read Full Article…
Washington Week: Congress Starts August Recess
Posted on 14. Aug, 2010 by Dr. Ellis in News and Updates
WASHINGTON (MedPage Today) — The House and Senate have adjourned for their summer recess, but an FDA advisory panel met on an epilepsy drug, and there’s been activity on the healthcare reform front.
Read Full Article…
Possibly Related Blogs
FDA Panel Says Yes to Epilepsy Drug
Posted on 11. Aug, 2010 by Dr. Ellis in News and Updates
(MedPage Today) — SILVER SPRING, Md. — An FDA advisory committee voted 13-0 Wednesday that ezogabine (Potiga) is an effective adjunctive treatment for epilepsy patients with partial-onset seizures.
Read Full Article…
Possibly Related Blogs
FDA Advisors to Consider Epilepsy Drug
Posted on 10. Aug, 2010 by Dr. Ellis in News and Updates
(MedPage Today) — An FDA advisory committee will meet Wednesday to decide whether to recommend approval of ezogabine (Potiva) for adjunctive treatment of partial-onset seizures in epilepsy patients.
Read Full Article…
Possibly Related Blogs
J&J Settles Topamax Marketing Case for $81 Million
Posted on 29. Apr, 2010 by Dr. Ellis in News and Updates
Johnson & Johnson has agreed to pay $81 million to settle charges that it improperly marketed its epilepsy drug topiramate (Topamax).
Read Full Article…
